UNOS分析:先天性心脏病儿童心室辅助装置作为移植桥接
该研究基于UNOS数据库2014至2023年3394例<18岁先天性心脏病(CHD)心脏移植等待者,比较使用与不使用心室辅助装置(VAD)桥接移植的结局。VAD支持者占16.5%,等待期死亡或恶化移除率为25.7%高于非VAD者的16.2%;移植后卒中、急性排斥及5年生存率两组无显著差异。
要点
- VAD桥接在CHD儿童移植等待者中比例从2014年20例增至2023年73例。
- VAD组等待期死亡或恶化移除率25.7%,非VAD组16.2%。
- 移植后卒中、急性排斥及5年生存率两组无显著差异。
核心结论
- 在<18岁CHD患者中,使用VAD桥接移植者的移植后结局和长期生存与未使用VAD者相似。
主要发现
- VAD支持者561/3394=16.5%,非VAD支持者2833/3394=83.5%。
- VAD组移植率70.6%(396/561),非VAD组65.4%(1852/2833)。
- 等待期死亡或恶化移除率总体17.7%(602/3394),VAD组25.7%(144/561),非VAD组16.2%(458/2833)。
关键数值与推荐
- VAD类型以Berlin Heart最常见(209/396=52.8%),配置多为左心室辅助装置(306/396=77.3%)。
临床怎么用
- 对于<18岁CHD心脏移植等待者,VAD桥接可作为策略,但需注意等待期死亡或恶化移除率较高。
局限性
- 本研究为回顾性数据库分析,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a multi-institutional contemporary cohort of patients < 18 years with congenital heart disease (CHD), we compare outcomes of bridge-to-transplant with and without ventricular assist device (VAD). METHODS: The United Network for Organ Sharing was queried for all patients <18 years with CHD listed for cardiac transplantation (January 1, 2014, to December 31, 2023). Patients were split into 2 cohorts based on the presence of VAD while on the waitlist. Univariable and multivariable analyses were performed to assess baseline characteristics and post-transplant survival. RESULTS: The overall patient cohort consisted of 3394 CHD patients listed for cardiac transplantation at 65 centres: 561/3394 = 16.5% had VAD support while on the waitlist and 2833/3394 = 83.5% did not. A total of 396/561 = 70.6% of VAD-supported patients and 1852/2833 = 65.4% of non-VAD-supported patients underwent cardiac transplantation. Waitlist mortality, defined as death or removal from waitlist due to clinical deterioration, was 602/3394 = 17.7% for all patients, 144/561 = 25.7% for VAD-supported patients, and 458/2833 = 16.2% for non-VAD-supported patients. Among the 2248 transplanted CHD patients transplanted at 65 centres (n = 396 VAD-supported, n = 1852 non-VAD-supported), Berlin Heart was the most frequently used VAD (209/396 = 52.8%), and VAD configuration was mostly left ventricular assist device (306/396 = 77.3%). VAD support among CHD patients < 18 bridged-to-transplant increased (20 in 2014, 73 in 2023). VAD-supported patients had similar rates of post-transplant stroke (25/389 = 6.4% vs 83/1835 = 4.5%, P = .145) and episodes of acute rejection (60/396 = 15.2% vs 305/1852 = 16.5%, P = .582) compared to non-VAD-supported patients. No significant differences between VAD-supported and non-VAD-supported patients were seen in longitudinal post-transplant survival up to 5 years (log-rank P = .257). CONCLUSIONS: In the last decade, patients <18 years with CHD bridged-to transplant with VAD achieve post-transplant outcomes and long-term survival similar to those bridged without VAD.
引用
- Bilgili A, Pendarvis J, Sharaf OM, et al. Analysis of UNOS: Ventricular Assist Device as Bridge-to-Transplant in Paediatric Patients With Congenital Heart Disease. Eur J Cardiothorac Surg. 2025. PMID: 40880296. doi:10.1093/ejcts/ezaf290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。